Graham Collins, Associate Professor, Haematology and Lymphoma Specialist at Oxford Cancer and Haematology Centre, shared on LinkedIn:
- “The importance of ASCT in primary CNS lymphoma – results of the IELSG43 trial.
- Ph3, 230 pts randomised
- MATRix x4 + BCNU/TT ASCT vs 2x R-DeVIC chemo (if at least PR with MATRix)
- 3y PFS 78% v 51%!
- OS also signif improvement
Convincing results. This is really great work establishing a key principle of management of primary CNS lymphoma: getting the patient to autograft is important. It also lays the groundwork for testing reduced induction regimens to see if more patients can get to transplant. This is the basis of the Optimate trial which has finished recruitment.”
Title: High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial
Authors: Gerald Illerhaus, Andrés J M Ferreri, Julia Wendler, Mascha Binder, Peter Borchmann, Justin Hasenkamp, Stephan Stilgenbauer, Alexander Röth, Gerlinde Egerer, Thomas Ernst, Thomas Weber, Bernd Hertenstein, Georg Lenz, Martin Dreyling, Robert Möhle, Guido Kobbe, Christian A Schmidt, Uta Brunnberg, Jens Panse, Michael Kneba, Thomas Heinicke, Sebastian Schroll, Thomas S Larsen, Lorenz Thurner, Tobias Pukrop, Hans Salwender, Ralph Naumann, Georg Hess, Frank P Kroschinsky, Anne K Blystad, Ulrich Keller, Elisa J Pulczynski, Martin Bjerregård Pedersen, Francesca Re, Lorella Orsucci, Lisa Pospiech, Paul La Rosée, Martina Deckert, Maurilio Ponzoni, Dennis Gmehlin, Matthias Backenstrass, Antje Jensch, Elke Valk, Teresa Calimeri, Benjamin Kasenda, Martin Trepel, Heidi Fricker, Inna Semenova, Florian Scherer, Philipp von Gottberg, Elvira Burger, Olga Grishina, Claudia Hader, Gabriele Ihorst, Jürgen Finke, Emanuele Zucca, Elisabeth Schorb.
Other articles featuring Graham Collins on OncoDaily.